New diabetes drug MK-2828 passes early safety check
NCT ID NCT07089784
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new medicine called MK-2828 in 46 adults with type 2 diabetes. The main goal was to see if the drug is safe and well-tolerated. Researchers also measured how the drug moves through the body and its effect on a marker of inflammation (hsCRP). This is a first step to see if MK-2828 might help control diabetes in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AMR Clinical ( Site 0003)
Knoxville, Tennessee, 37920, United States
-
AMR Lexington ( Site 0012)
Lexington, Kentucky, 40509, United States
-
Advanced Pharma CR, LLC ( Site 0001)
Miami, Florida, 33147, United States
-
Alliance for Multispecialty Research, LLC ( Site 0013)
Kansas City, Missouri, 64114, United States
-
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0009)
Springfield, Missouri, 65802, United States
-
California Clinical Trials Medical Group managed by PAREXEL ( Site 0008)
Glendale, California, 91206, United States
-
ICON Early Phase Services ( Site 0006)
San Antonio, Texas, 78209, United States
-
Jacksonville Center for Clinical Research ( Site 0002)
Jacksonville, Florida, 32216, United States
-
ProSciento Inc. ( Site 0004)
Chula Vista, California, 91911, United States
-
QPS Miami Research Associates ( Site 0005)
South Miami, Florida, 33143, United States
-
Velocity Clinical Research, Hallandale Beach ( Site 0010)
Hallandale, Florida, 33009, United States